IM-1021
Antibody–drug conjugate
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: data expected in 2026 (Immunome, Inc., 9 Nov 2026). “In November 2025, we reported observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021, and we plan to share initial data in 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06823167 NCT06823167 · Advanced ROR1-Expressing Solid Tumors and Lymphomas Registry: NCT06823167 | 1 | Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs) (From first dose to 37 days following last dose of study treatment); Determine the recommended dose(s) and schedule(s) of IM-1021 for further development (From first dose to 37 days following last dose of study treatment) 2028-05 | In progress: results expected 1 May 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other ROR1 drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| IM-1021: this drug | Phase 1 | Antibody–drug conjugate | ROR1 | not yet graded | No reviewed efficacy summary | |
| Zilovertamab Vedotin | Phase 2/3(overall) | Antibody–drug conjugate | ROR1 | not yet graded | No reviewed efficacy summary |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow IM-1021 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.